Indivior to Release Q3 2026 Financial Results

RICHMOND, Va., Oct. 19, 2026 /CourierPR/ -- Indivior Pharmaceuticals, Inc., a leading pharmaceutical company focused on treating opioid use disorder (OUD), has announced its intention to release its third quarter 2026 financial results on Thursday, October 29, 2026. The results will be made available at 7:00 a.m. U.S. Eastern Daylight Time (EDT).

Indivior has been a pioneer in the field of long-acting injectable treatments for OUD for over 25 years. During this period, the company has significantly advanced the science of addiction medicine by developing treatments that support individuals in their journey towards long-term recovery. These treatments offer people independence and dignity, empowering them to lead fulfilling lives.

Over the years, Indivior has remained committed to its mission of helping individuals living with OUD. The company's commitment is underpinned by its core values of compassion, integrity, and science. By working closely with people living with OUD, public health champions, and communities, Indivior is actively contributing to the power of recovery and the renewal of hope.

The financial results for the third quarter of 2026 are expected to provide a comprehensive overview of the company's financial performance during this period. These results will be made available on the company's website at www.indivior.com, allowing stakeholders to access the information at their convenience.

Indivior Pharmaceuticals, Inc., continues to be at the forefront of the pharmaceutical industry, dedicated to advancing the understanding of OUD as a chronic but treatable brain disease. As the company looks to the future, it remains committed to its mission of delivering evidence-based treatment and supporting individuals on their path to recovery.